Low-Dose Sirolimus for Platelet Disorder

This trial aims to determine if low-dose sirolimus is safe and effective for treating individuals with RUNX1 familial platelet disorder (FPD), a rare condition affecting blood cells and increasing cancer risk. Sirolimus, typically used to prevent organ rejection, may help prevent RUNX1-FPD from progressing to certain cancers. Individuals with a confirmed RUNX1 gene mutation who can provide a bone marrow sample might qualify for this trial. As a Phase 1 trial, the research focuses on understanding the treatment's effects in participants, offering them a chance to contribute to groundbreaking research.

Research has shown that sirolimus is usually well-tolerated. Studies have found that it can quickly increase platelet counts, benefiting those with blood disorders. Some patients have used sirolimus as a backup treatment for challenging platelet disorders, with positive results.

Most treatments for platelet disorders focus on managing symptoms through blood transfusions or medications like corticosteroids that suppress the immune system. But sirolimus works differently, targeting the underlying causes by modulating the immune response and reducing inflammation. Researchers are excited about sirolimus because it's an immunosuppressant that may offer a more targeted approach with potentially fewer side effects. This treatment could provide a new option for patients who don't respond well to current therapies.

Research has shown that sirolimus may help with blood issues similar to those in RUNX1 familial platelet disorder (FPD). In studies with patients who have immune thrombocytopenia (ITP), a condition characterized by low platelet counts, sirolimus successfully increased platelet levels. For example, one study found that 69.7% of patients responded to sirolimus treatment within three months. Another study demonstrated that 55% of patients had a positive response in just one month. Although sirolimus is primarily used for organ transplant patients, its ability to adjust immune responses suggests it might be helpful for conditions like RUNX1-FPD. This trial will evaluate sirolimus as a potential option for preventing RUNX1-FPD from progressing to more serious conditions like cancer.²³⁶⁷⁸